CM
PCVX icon

Caption Management’s Vaxcyte PCVX Stock Holding History

Caption Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.6M Buy
303,000
+273,000
+910% +$14.8M 0.1% 210
2025
Q4 		$1.38M Sell
30,000
-20,000
-40% -$895K 0.01% 949
2025
Q3 		$1.8M Buy
+50,000
New +$1.66M 0.01% 883
2025
Q2 		– Sell
-25,000
Closed -$944K – 1787
2025
Q1 		$944K Sell
25,000
-120,800
-83% -$9.66M 0.01% 942
2024
Q4 		$11.9M Sell
145,800
-29,200
-17% -$2.9M 0.11% 155
2024
Q3 		$20M Buy
175,000
+152,500
+678% +$13.7M 0.32% 66
2024
Q2 		$1.7M Buy
+22,500
New +$1.53M 0.03% 520
2023
Q3 		– Sell
-60,000
Closed -$3M – 1473
2023
Q2 		$3M Hold
60,000
– – 0.05% 398
2023
Q1 		$2.25M Buy
60,000
+30,000
+100% +$1.27M 0.04% 415
2022
Q4 		$1.44M Buy
+30,000
New +$1.18M 0.02% 641

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caption Management's PCVX Position: Q2 2025 in Review

Caption Management sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 44,200 shares — an estimated $1.67M sold.

Caption Management first reported a position in PCVX in Q3 2022 and held it in 6 quarters. The position peaked at $6.25M in Q3 2024. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

  • Caption Management reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
  • Caption Management sold 44,200 Vaxcyte shares in Q2 2025, an estimated $1.67M.
  • Caption Management first reported a position in Vaxcyte in Q3 2022 and held it in 6 quarters.
  • Caption Management's Vaxcyte position peaked at $6.25M in Q3 2024.
  • 294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.